Related Experiment Videos
Anemia and heart failure: a community study
Shannon M Dunlay1, Susan A Weston, Margaret M Redfield
1Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Insights
Anemia affects half of heart failure patients, with prevalence increasing over time. This condition, particularly in preserved ejection fraction heart failure, significantly raises mortality risk.
Area of Science:
- Cardiology
- Hematology
- Epidemiology
Background:
- Anemia is a significant comorbidity in heart failure (HF), linked to increased mortality.
- Understanding anemia prevalence and its impact is crucial for HF management.
Purpose of the Study:
- To determine the prevalence of anemia in a community HF population.
- To analyze trends in anemia prevalence over time.
- To evaluate the role of anemia in HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF).
Main Methods:
- Retrospective (1979-2002, n=1063) and prospective (2003-2006, n=677) cohorts of Olmsted County residents with HF were analyzed.
- Clinical characteristics were collected, and anemia was defined using World Health Organization criteria.
Main Results:
- Anemia prevalence was 40% in the retrospective cohort and 53% in the prospective cohort.
- Anemia prevalence increased by 16% from 1979-2002 and was higher in HFpEF (58%) versus HFrEF (48%).
- Anemia significantly increased mortality risk (P<.001), with a J-shaped relationship between hemoglobin levels and mortality.
Conclusions:
- Approximately half of community heart failure patients are anemic, with rising prevalence.
- Anemia is more common in HFpEF and is a strong predictor of increased mortality in HF patients.
Purpose:
Anemia is an important comorbidity in heart failure and has been associated with increased mortality. The goals of this study were to define the prevalence of anemia in a community population with heart failure, examine trends in prevalence over time, and evaluate the role of anemia in patients with heart failure with preserved and reduced ejection fraction.
Methods:
Two cohorts of Olmsted County residents with heart failure were examined. The retrospective cohort included incident heart failure cases from 1979 to 2002 (n=1063). The prospective cohort included active heart failure cases from 2003 to 2006 (n=677). Clinical characteristics were collected. Anemia was defined by World Health Organization criteria.
Results:
The prevalence of anemia was 40% in the retrospective cohort and 53% in the prospective cohort. Anemia prevalence increased by an estimated 16% between 1979 and 2002 (P=.008) and was higher in those with preserved (> or =50%) versus reduced (<50%) ejection fraction (58% vs 48%, respectively, P<.001) from 2003 to 2006. Anemia was associated with a large increase in the risk of death (P<.001 both cohorts). The relationship between mortality and hemoglobin followed a J-shaped curve, with increased mortality with hemoglobin levels less than 14 mg/dL and greater than 16 mg/dL. In the prospective cohort, after adjustment for clinical characteristics, the hazard ratios (95% confidence interval) for death were 3.07 (1.26-6.82) in those with a hemoglobin level of 16 mg/dL or more and 2.39 (1.37-4.27) in those with a hemoglobin level less than 10 mg/dL, using hemoglobin 14 to 16 mg/dL as the referent.
Conclusion:
In the community, half of patients with heart failure are anemic, and the prevalence of anemia has increased over time. Anemia is more prevalent in heart failure with preserved ejection fraction and is associated with a large increase in mortality.
Related Concept Videos
Heart Failure I: Introduction
Heart Failure VII: Nursing Interventions
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure VI: Adjunct Therapies
Pathophysiology of Heart Failure